Swedish Medical Center
56
7
7
30
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
16.1%
9 terminated/withdrawn out of 56 trials
76.9%
-9.6% vs industry average
9%
5 trials in Phase 3/4
10%
3 of 30 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (56)
Statins In Intracerbral Hemorrhage
Role: collaborator
Gravity Versus Vacuum Based Indwelling Tunneled Pleural Drainage System
Role: collaborator
Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
Role: collaborator
Machine Learning Prediction of Possible Central Line Associated Blood Stream Infections and Rate of Reduction
Role: lead
Minimally Invasive Esophagectomy Pain Control Trial
Role: lead
Tumor Rupture During Robotic Partial Nephrectomy
Role: collaborator
Personalized Cancer Stem Cell High-Throughput Drug Screening for Glioblastoma
Role: lead
Early Chest Tube Removal After Surgery for Primary Spontaneous Pneumothorax: A Randomized Controlled Trial
Role: lead
Cancer Stem Cell High-Throughput Drug Screening Study
Role: lead
Validation of HRM Score for the GERD Diagnosis
Role: collaborator
Rectal Versus Oral Diazepam Administration in the Treatment of Levator Ani Syndrome
Role: lead
A Trial Comparing Transversus Abdominis Plane Catheter Versus Epidural After Esophagectomy
Role: lead
Gamma Knife Radiosurgery for Treatment of Essential Tremor
Role: lead
Management of Pleural Space Infections
Role: lead
Vitamin D Supplementation in Multiple Sclerosis
Role: collaborator
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
Role: lead
Staple vs. Suture in Robotic Prostatectomy
Role: lead
Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL
Role: lead
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
Role: lead
Unobtrusive Sensing of Medication Intake ("USE-MI")
Role: lead